NO326452B1 - Anvendelse av et enkeltkjede-antistoff eller en nukleinsyre som koder for dette for fremstilling av en farmasoytisk sammensetning for behandling av cancer hvor et mutert p53 protein er involvert, samt 11D3 molekylet og nukleinsyren som koder for dette og sammensetninger omfattende disse. - Google Patents

Anvendelse av et enkeltkjede-antistoff eller en nukleinsyre som koder for dette for fremstilling av en farmasoytisk sammensetning for behandling av cancer hvor et mutert p53 protein er involvert, samt 11D3 molekylet og nukleinsyren som koder for dette og sammensetninger omfattende disse. Download PDF

Info

Publication number: NO326452B1
Authority: NO; Norway
Prior art keywords: protein; nucleic acid; vector; mutated; cancer
Prior art date: 1996-10-29

Application number

NO19991729A

Other languages

English (en)

Norwegian (no)

Other versions

NO991729L (no

NO991729D0 (no

Inventor

Laurent Debussche

Laurent Bracco

Original Assignee

Aventis Pharma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-10-29

Filing date

1999-04-13

Publication date

2008-12-08

1999-04-13 Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa

1999-04-13 Publication of NO991729L publication Critical patent/NO991729L/no

1999-04-13 Publication of NO991729D0 publication Critical patent/NO991729D0/no

2008-12-08 Publication of NO326452B1 publication Critical patent/NO326452B1/no

Links

102100025064 Cellular tumor antigen p53 Human genes 0.000 title claims abstract description 101
150000007523 nucleic acids Chemical class 0.000 title claims abstract description 53
102000039446 nucleic acids Human genes 0.000 title claims abstract description 51
108020004707 nucleic acids Proteins 0.000 title claims abstract description 51
206010028980 Neoplasm Diseases 0.000 title claims description 25
238000011282 treatment Methods 0.000 title claims description 13
201000011510 cancer Diseases 0.000 title claims description 12
239000000203 mixture Substances 0.000 title claims description 8
239000008194 pharmaceutical composition Substances 0.000 title claims description 8
238000002360 preparation method Methods 0.000 title claims description 7
239000013598 vector Substances 0.000 claims abstract description 46
108090000623 proteins and genes Proteins 0.000 claims description 69
102000004169 proteins and genes Human genes 0.000 claims description 46
241000701161 unidentified adenovirus Species 0.000 claims description 24
230000002950 deficient Effects 0.000 claims description 15
241001430294 unidentified retrovirus Species 0.000 claims description 14
230000027455 binding Effects 0.000 claims description 8
239000013603 viral vector Substances 0.000 claims description 8
210000004899 c-terminal region Anatomy 0.000 claims description 5
206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
208000020816 lung neoplasm Diseases 0.000 claims description 3
201000005202 lung cancer Diseases 0.000 claims description 2
208000003174 Brain Neoplasms Diseases 0.000 claims 1
201000003741 Gastrointestinal carcinoma Diseases 0.000 claims 1
201000010536 head and neck cancer Diseases 0.000 claims 1
208000014829 head and neck neoplasm Diseases 0.000 claims 1
201000002313 intestinal cancer Diseases 0.000 claims 1
201000007270 liver cancer Diseases 0.000 claims 1
208000014018 liver neoplasm Diseases 0.000 claims 1
238000001727 in vivo Methods 0.000 abstract description 19
238000000338 in vitro Methods 0.000 abstract description 14
238000013518 transcription Methods 0.000 abstract description 8
230000035897 transcription Effects 0.000 abstract description 8
230000004568 DNA-binding Effects 0.000 abstract description 6
230000001173 tumoral effect Effects 0.000 abstract description 4
239000012190 activator Substances 0.000 abstract description 3
210000004027 cell Anatomy 0.000 description 47
230000006870 function Effects 0.000 description 42
238000000034 method Methods 0.000 description 39
108020004414 DNA Proteins 0.000 description 20
102000053602 DNA Human genes 0.000 description 20
238000010276 construction Methods 0.000 description 14
230000035772 mutation Effects 0.000 description 13
230000000694 effects Effects 0.000 description 12
108020004635 Complementary DNA Proteins 0.000 description 11
241000700605 Viruses Species 0.000 description 11
210000004881 tumor cell Anatomy 0.000 description 11
230000001413 cellular effect Effects 0.000 description 10
210000004408 hybridoma Anatomy 0.000 description 10
239000013612 plasmid Substances 0.000 description 10
150000001413 amino acids Chemical class 0.000 description 9
239000000523 sample Substances 0.000 description 9
238000010804 cDNA synthesis Methods 0.000 description 8
239000002299 complementary DNA Substances 0.000 description 8
239000000499 gel Substances 0.000 description 8
230000003463 hyperproliferative effect Effects 0.000 description 8
238000012546 transfer Methods 0.000 description 8
230000003993 interaction Effects 0.000 description 7
238000012216 screening Methods 0.000 description 7
241000702421 Dependoparvovirus Species 0.000 description 6
238000012217 deletion Methods 0.000 description 6
230000037430 deletion Effects 0.000 description 6
239000012634 fragment Substances 0.000 description 6
108090000765 processed proteins & peptides Proteins 0.000 description 6
239000000126 substance Substances 0.000 description 6
230000002103 transcriptional effect Effects 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
108091028043 Nucleic acid sequence Proteins 0.000 description 5
238000013459 approach Methods 0.000 description 5
239000013604 expression vector Substances 0.000 description 5
230000014759 maintenance of location Effects 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
230000004048 modification Effects 0.000 description 5
238000012986 modification Methods 0.000 description 5
239000000047 product Substances 0.000 description 5
108020003175 receptors Proteins 0.000 description 5
102000005962 receptors Human genes 0.000 description 5
229920002477 rna polymer Polymers 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
239000006228 supernatant Substances 0.000 description 5
238000001890 transfection Methods 0.000 description 5
102000002260 Alkaline Phosphatase Human genes 0.000 description 4
108020004774 Alkaline Phosphatase Proteins 0.000 description 4
108700028369 Alleles Proteins 0.000 description 4
208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 4
241000701044 Human gammaherpesvirus 4 Species 0.000 description 4
108091023040 Transcription factor Proteins 0.000 description 4
102000040945 Transcription factor Human genes 0.000 description 4
108010040002 Tumor Suppressor Proteins Proteins 0.000 description 4
102000001742 Tumor Suppressor Proteins Human genes 0.000 description 4
-1 a-actin Proteins 0.000 description 4
229920006317 cationic polymer Polymers 0.000 description 4
239000000284 extract Substances 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
230000007170 pathology Effects 0.000 description 4
108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 3
102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
241001135569 Human adenovirus 5 Species 0.000 description 3
241001529936 Murinae Species 0.000 description 3
108010021466 Mutant Proteins Proteins 0.000 description 3
102000008300 Mutant Proteins Human genes 0.000 description 3
108700005077 Viral Genes Proteins 0.000 description 3
230000003321 amplification Effects 0.000 description 3
230000033228 biological regulation Effects 0.000 description 3
230000007547 defect Effects 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
230000010534 mechanism of action Effects 0.000 description 3
238000003199 nucleic acid amplification method Methods 0.000 description 3
239000002773 nucleotide Substances 0.000 description 3
125000003729 nucleotide group Chemical group 0.000 description 3
108700025694 p53 Genes Proteins 0.000 description 3
239000013600 plasmid vector Substances 0.000 description 3
238000000746 purification Methods 0.000 description 3
208000037803 restenosis Diseases 0.000 description 3
230000001177 retroviral effect Effects 0.000 description 3
238000012360 testing method Methods 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
241001529453 unidentified herpesvirus Species 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
241000282465 Canis Species 0.000 description 2
101150007452 EBNA-LP gene Proteins 0.000 description 2
241000282412 Homo Species 0.000 description 2
241000341655 Human papillomavirus type 16 Species 0.000 description 2
208000008839 Kidney Neoplasms Diseases 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
206010030155 Oesophageal carcinoma Diseases 0.000 description 2
241000256251 Spodoptera frugiperda Species 0.000 description 2
230000004913 activation Effects 0.000 description 2
239000000427 antigen Substances 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
230000006907 apoptotic process Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
125000002091 cationic group Chemical group 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
238000010367 cloning Methods 0.000 description 2
210000001072 colon Anatomy 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
108700004026 gag Genes Proteins 0.000 description 2
238000002744 homologous recombination Methods 0.000 description 2
230000006801 homologous recombination Effects 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
239000003446 ligand Substances 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
101150024228 mdm2 gene Proteins 0.000 description 2
239000012528 membrane Substances 0.000 description 2
238000002703 mutagenesis Methods 0.000 description 2
231100000350 mutagenesis Toxicity 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
230000035515 penetration Effects 0.000 description 2
210000001322 periplasm Anatomy 0.000 description 2
230000004481 post-translational protein modification Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
230000017854 proteolysis Effects 0.000 description 2
230000010076 replication Effects 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
238000003146 transient transfection Methods 0.000 description 2
238000010798 ubiquitination Methods 0.000 description 2
241000701447 unidentified baculovirus Species 0.000 description 2
OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 description 1
LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
108010002913 Asialoglycoproteins Proteins 0.000 description 1
241000271566 Aves Species 0.000 description 1
101100381862 Bacillus subtilis (strain 168) bmr3 gene Proteins 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
206010005949 Bone cancer Diseases 0.000 description 1
208000018084 Bone neoplasm Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000701157 Canine mastadenovirus A Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
108090000565 Capsid Proteins Proteins 0.000 description 1
102100038909 Caveolin-2 Human genes 0.000 description 1
102100023321 Ceruloplasmin Human genes 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 1
108020003215 DNA Probes Proteins 0.000 description 1
239000003298 DNA probe Substances 0.000 description 1
230000033616 DNA repair Effects 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000001690 Factor VIII Human genes 0.000 description 1
108010054218 Factor VIII Proteins 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
101000740981 Homo sapiens Caveolin-2 Proteins 0.000 description 1
241000598171 Human adenovirus sp. Species 0.000 description 1
241000701806 Human papillomavirus Species 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
108010058683 Immobilized Proteins Proteins 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
102100023915 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102100021244 Integral membrane protein GPR180 Human genes 0.000 description 1
102000011782 Keratins Human genes 0.000 description 1
108010076876 Keratins Proteins 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
241000713869 Moloney murine leukemia virus Species 0.000 description 1
241000713862 Moloney murine sarcoma virus Species 0.000 description 1
108010077850 Nuclear Localization Signals Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
229920002873 Polyethylenimine Polymers 0.000 description 1
108010039918 Polylysine Proteins 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
101710132594 Protein E6 Proteins 0.000 description 1
108020005115 Pyruvate Kinase Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
241000714474 Rous sarcoma virus Species 0.000 description 1
101100379247 Salmo trutta apoa1 gene Proteins 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
241000713896 Spleen necrosis virus Species 0.000 description 1
101100289792 Squirrel monkey polyomavirus large T gene Proteins 0.000 description 1
101100344811 Starmerella bombicola mdr gene Proteins 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
206010043515 Throat cancer Diseases 0.000 description 1
208000024770 Thyroid neoplasm Diseases 0.000 description 1
102000004243 Tubulin Human genes 0.000 description 1
108090000704 Tubulin Proteins 0.000 description 1
108090000848 Ubiquitin Proteins 0.000 description 1
102000044159 Ubiquitin Human genes 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
102000013127 Vimentin Human genes 0.000 description 1
108010065472 Vimentin Proteins 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
241000607479 Yersinia pestis Species 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000002424 anti-apoptotic effect Effects 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
238000003782 apoptosis assay Methods 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
102000023732 binding proteins Human genes 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
238000002659 cell therapy Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
239000002131 composite material Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
238000012258 culturing Methods 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000001934 delay Effects 0.000 description 1
230000001687 destabilization Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
108700004025 env Genes Proteins 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
229960000301 factor viii Drugs 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
101150098622 gag gene Proteins 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000003053 immunization Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
210000003963 intermediate filament Anatomy 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000003093 intracellular space Anatomy 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000002502 liposome Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
201000005296 lung carcinoma Diseases 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
108020004084 membrane receptors Proteins 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
239000003471 mutagenic agent Substances 0.000 description 1
208000025113 myeloid leukemia Diseases 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
210000005044 neurofilament Anatomy 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
210000000633 nuclear envelope Anatomy 0.000 description 1
238000006384 oligomerization reaction Methods 0.000 description 1
229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
108700004029 pol Genes Proteins 0.000 description 1
229920000656 polylysine Polymers 0.000 description 1
230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000005522 programmed cell death Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000008439 repair process Effects 0.000 description 1
229930002330 retinoic acid Natural products 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000003270 steroid hormone Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
230000001629 suppression Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
229960001727 tretinoin Drugs 0.000 description 1
230000005748 tumor development Effects 0.000 description 1
230000034512 ubiquitination Effects 0.000 description 1
238000005199 ultracentrifugation Methods 0.000 description 1
230000002792 vascular Effects 0.000 description 1
108090000195 villin Proteins 0.000 description 1
210000005048 vimentin Anatomy 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000001262 western blot Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Immunology (AREA)
Zoology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO19991729A 1996-10-29 1999-04-13 Anvendelse av et enkeltkjede-antistoff eller en nukleinsyre som koder for dette for fremstilling av en farmasoytisk sammensetning for behandling av cancer hvor et mutert p53 protein er involvert, samt 11D3 molekylet og nukleinsyren som koder for dette og sammensetninger omfattende disse. NO326452B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9613176A FR2755144B1 (fr)	1996-10-29	1996-10-29	Fragments d'anticorps a chaine unique anti-p53 et utilisation
PCT/FR1997/001921 WO1998018825A1 (fr)	1996-10-29	1997-10-27	Fragments d'anticorps a chaine unique anti-p53 et utilisations

Publications (3)

Publication Number	Publication Date
NO991729L NO991729L (no)	1999-04-13
NO991729D0 NO991729D0 (no)	1999-04-13
NO326452B1 true NO326452B1 (no)	2008-12-08

Family

ID=9497134

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19991729A NO326452B1 (no)	1996-10-29	1999-04-13	Anvendelse av et enkeltkjede-antistoff eller en nukleinsyre som koder for dette for fremstilling av en farmasoytisk sammensetning for behandling av cancer hvor et mutert p53 protein er involvert, samt 11D3 molekylet og nukleinsyren som koder for dette og sammensetninger omfattende disse.

Country Status (21)

Country	Link
US (1)	US6852509B1 (pt)
EP (1)	EP0941252B1 (pt)
JP (1)	JP4371178B2 (pt)
KR (1)	KR100874789B1 (pt)
AT (1)	ATE380198T1 (pt)
AU (1)	AU745530B2 (pt)
BR (1)	BR9712575A (pt)
CA (1)	CA2268865C (pt)
CZ (1)	CZ300526B6 (pt)
DE (1)	DE69738352T2 (pt)
DK (1)	DK0941252T3 (pt)
ES (1)	ES2297853T3 (pt)
FR (1)	FR2755144B1 (pt)
HU (1)	HU226330B1 (pt)
IL (2)	IL129476A0 (pt)
NO (1)	NO326452B1 (pt)
PT (1)	PT941252E (pt)
SI (1)	SI0941252T1 (pt)
SK (1)	SK286978B6 (pt)
WO (1)	WO1998018825A1 (pt)
ZA (1)	ZA979738B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL121041A0 (en)	1997-06-09	1997-11-20	Yeda Res & Dev	Immunogenic compositions for induction of anti-tumor immunity
US7199809B1 (en)	1998-10-19	2007-04-03	Symyx Technologies, Inc.	Graphic design of combinatorial material libraries
AU769679B2 (en) *	1999-03-19	2004-01-29	St Vincent's Hospital Sydney Limited	Anti-p53 antibodies
AUPP932199A0 (en) *	1999-03-19	1999-04-15	St Vincent's Hospital Sydney Limited	Anti-p53 antibodies
DE19962583A1 (de) *	1999-12-23	2001-06-28	Mueller Hermelink Hans Konrad	Antikörper gegen Plasmazellen
US6630584B1 (en) *	2000-03-16	2003-10-07	Ramot At Tel-Aviv University Ltd.	Single chain antibody against mutant p53
US20080039409A1 (en) *	2003-12-24	2008-02-14	Locomogene, Inc.	Method of Suppressing Cancer
JPWO2005061007A1 (ja) *	2003-12-24	2007-07-12	学校法人聖マリアンナ医科大学	癌の抑制方法
GB0420771D0 (en) *	2004-09-17	2004-10-20	Randox Lab Ltd	Antibody
WO2006100681A2 (en) *	2005-03-25	2006-09-28	Ramot At Tel Aviv University Ltd.	Human synthetic single-chain antibodies directed against the common epitope of mutant p53 and their uses
WO2007028117A2 (en) *	2005-09-02	2007-03-08	New England Medical Center Hospitals, Inc.	P8 as a marker for heart failure
JP7481726B2 (ja) *	2016-05-02	2024-05-13	プロセナバイオサイエンシーズリミテッド	タウ認識抗体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9224784D0 (en) *	1992-11-26	1993-01-13	Univ Dundee	Cellular protein
FR2732348B1 (fr) *	1995-03-31	1997-04-30	Rhone Poulenc Rorer Sa	Systeme d'expression conditionnel
FR2736915B1 (fr) *	1995-07-19	1997-08-22	Rhone Poulenc Rorer Sa	Variants de la proteine p53 et utilisations therapeutiques

1996
- 1996-10-29 FR FR9613176A patent/FR2755144B1/fr not_active Expired - Fee Related
1997
- 1997-10-27 AU AU49520/97A patent/AU745530B2/en not_active Ceased
- 1997-10-27 AT AT97912262T patent/ATE380198T1/de active
- 1997-10-27 KR KR1019997003679A patent/KR100874789B1/ko not_active IP Right Cessation
- 1997-10-27 PT PT97912262T patent/PT941252E/pt unknown
- 1997-10-27 ES ES97912262T patent/ES2297853T3/es not_active Expired - Lifetime
- 1997-10-27 DK DK97912262T patent/DK0941252T3/da active
- 1997-10-27 HU HU9904199A patent/HU226330B1/hu not_active IP Right Cessation
- 1997-10-27 EP EP97912262A patent/EP0941252B1/fr not_active Expired - Lifetime
- 1997-10-27 BR BR9712575-0A patent/BR9712575A/pt not_active Application Discontinuation
- 1997-10-27 SI SI9730778T patent/SI0941252T1/sl unknown
- 1997-10-27 IL IL12947697A patent/IL129476A0/xx unknown
- 1997-10-27 SK SK558-99A patent/SK286978B6/sk not_active IP Right Cessation
- 1997-10-27 CA CA2268865A patent/CA2268865C/fr not_active Expired - Fee Related
- 1997-10-27 CZ CZ0145599A patent/CZ300526B6/cs not_active IP Right Cessation
- 1997-10-27 JP JP52011998A patent/JP4371178B2/ja not_active Expired - Fee Related
- 1997-10-27 US US09/297,181 patent/US6852509B1/en not_active Expired - Fee Related
- 1997-10-27 WO PCT/FR1997/001921 patent/WO1998018825A1/fr active IP Right Grant
- 1997-10-27 DE DE69738352T patent/DE69738352T2/de not_active Expired - Lifetime
- 1997-10-29 ZA ZA9709738A patent/ZA979738B/xx unknown
1999
- 1999-04-13 NO NO19991729A patent/NO326452B1/no not_active IP Right Cessation
- 1999-04-15 IL IL129476A patent/IL129476A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
DE69738352D1 (de)	2008-01-17
SI0941252T1 (sl)	2008-04-30
ATE380198T1 (de)	2007-12-15
ZA979738B (en)	1998-05-22
HU226330B1 (en)	2008-09-29
KR100874789B1 (ko)	2008-12-18
AU745530B2 (en)	2002-03-21
CZ145599A3 (cs)	1999-08-11
SK55899A3 (en)	2000-06-12
IL129476A (en)	2010-05-17
JP4371178B2 (ja)	2009-11-25
AU4952097A (en)	1998-05-22
DK0941252T3 (da)	2008-03-31
CA2268865C (fr)	2011-01-04
WO1998018825A1 (fr)	1998-05-07
JP2001502553A (ja)	2001-02-27
ES2297853T3 (es)	2008-05-01
BR9712575A (pt)	1999-10-19
CA2268865A1 (fr)	1998-05-07
SK286978B6 (sk)	2009-08-06
FR2755144A1 (fr)	1998-04-30
NO991729L (no)	1999-04-13
US6852509B1 (en)	2005-02-08
HUP9904199A1 (hu)	2000-04-28
IL129476A0 (en)	2000-02-29
NO991729D0 (no)	1999-04-13
HUP9904199A3 (en)	2000-09-28
KR20000052845A (ko)	2000-08-25
FR2755144B1 (fr)	1998-11-27
EP0941252A1 (fr)	1999-09-15
PT941252E (pt)	2008-03-07
DE69738352T2 (de)	2008-11-13
EP0941252B1 (fr)	2007-12-05
CZ300526B6 (cs)	2009-06-10

Legal Events

Date	Code	Title	Description
2013-05-27	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
US20080311608A1 (en)	2008-12-18	Antagonist of the oncogenic activity of the protein MDM2, and use thereof in the treatment of cancers
US20050233963A1 (en)	2005-10-20	Heat shock response and virus replication
NO326452B1 (no)	2008-12-08	Anvendelse av et enkeltkjede-antistoff eller en nukleinsyre som koder for dette for fremstilling av en farmasoytisk sammensetning for behandling av cancer hvor et mutert p53 protein er involvert, samt 11D3 molekylet og nukleinsyren som koder for dette og sammensetninger omfattende disse.
NO322477B1 (no)	2006-10-09	P53 variant, nukleinsyre, ekspresjonskassett, vektor, farmasoytisk preparat samt anvendelse for fremstilling av et farmasoytisk preparat for behandling av hyperproliferative lidelse.
US5717058A (en)	1998-02-10	Peptide inhibitors of tax-dependent transcription
SK131197A3 (en)	1998-05-06	Conditional expression system
US6544948B1 (en)	2003-04-08	ΔP62, variants thereof, amino acid sequences coding therefor and their uses in gene therapy for cancer
MXPA97006928A (es)	1998-07-03	Sistema de expresion condicional
MXPA97008877A (en)	1998-10-15	P62, its variants, the nucleic acid sequences that code them, and its use in anti-cancer gene therapy
MXPA98001407A (en)	1998-10-23	Antagonists of the oncogenic activity of the mdm2 protein, and its use in the treatment of the cance